Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

4.55
+0.02000.44%
Volume:215.78K
Turnover:975.37K
Market Cap:275.11M
PE:-0.98
High:4.57
Open:4.51
Low:4.47
Close:4.53
52wk High:9.94
52wk Low:4.27
Shares:60.46M
Float Shares:47.66M
Volume Ratio:0.40
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6291
EPS(LYR):-3.7413
ROE:-77.81%
ROA:-22.38%
PB:1.25
PE(LYR):-1.22

Loading ...

Vanda Pharmaceuticals Price Target Maintained with a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 05

Vanda Pharmaceuticals: Buy Rating Reaffirmed as HETLIOZ Phase 3 Success in DSWPD Supports sNDA; $20 Price Target Maintained

TIPRANKS
·
Oct 05

Can Vanda Pharmaceuticals (NASDAQ:VNDA) Afford To Invest In Growth?

Simply Wall St.
·
Oct 05

Vanda Presents New Gemini-1 Data on Imsidolimab in Generalized Pustular Psoriasis at EADV 2026

Reuters
·
Oct 02

Vanda's Late-Stage Trial of Sleep Disorder Drug Meets Primary Goal

MT Newswires Live
·
Sep 30

Vanda Pharmaceuticals reports results from pivotal Phase III study of HETLIOZ

TIPRANKS
·
Sep 30

Vanda Pharmaceuticals up 33% after Phase 3 Hetlioz study met primary endpoint

TIPRANKS
·
Sep 30

Vanda Says Phase III Trial Shows Hetlioz Advances Sleep Onset in Delayed Sleep-Wake Phase Disorder

Reuters
·
Sep 30

Vanda Plans FDA sNDA Filing for Hetlioz in Delayed Sleep-Wake Phase Disorder

Reuters
·
Sep 30

Vanda Pharmaceuticals - no New Safety Signals Identified in Phase Iii Study for Hetlioz

THOMSON REUTERS
·
Sep 30

Vanda Pharmaceuticals - Phase Iii Study Met Primary Endpoint with 37.1 Minute Sleep Onset Shift vs Placebo

THOMSON REUTERS
·
Sep 30

Vanda Pharmaceuticals Announces Positive Phase Iii Results for Hetlioz®(Tasimelteon) in Delayed Sleep-Wake Phase Disorder

THOMSON REUTERS
·
Sep 30

Vanda Pharmaceuticals Inc : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $10

THOMSON REUTERS
·
Sep 23

BetterLife Pharma Names Charles Duncan Audit Committee Chair, Appoints Him Director

Reuters
·
Sep 11

Vanda Pharma to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 03

Vanda Says EU Grants Orphan Drug Status to Imsidolimab for Generalized Pustular Psoriasis

Reuters
·
Aug 24

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

THOMSON REUTERS
·
Aug 24

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Vanda (VNDA) and AbCellera Biologics (ABCL)

TIPRANKS
·
Aug 10

B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating

MT Newswires Live
·
Aug 10

Vanda Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 10